Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).

The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available later that day.

About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor ContactMatt Scalo(801) 584-3532IR@myriad.com

Media ContactGlenn Farrell(385) 318-3718PR@myriad.com

Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Myriad Genetics Charts.
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Myriad Genetics Charts.